CD33 and Alzheimer disease: Similarly, another study demonstrated that the Alzheimer’s disease-associated SIGLEC3 risk variant increases the expression of the full-length sialic acid-binding isoform, which enhances inhibitory signaling and reduces microglial Aβ clearance.